BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,731,336 | +6.4% | 385,782 | +5.8% | 0.00% | 0.0% |
| Q2 2023 | $2,566,538 | +77.5% | 364,565 | +110.3% | 0.00% | 0.0% |
| Q1 2023 | $1,446,031 | -23.6% | 173,385 | +5.2% | 0.00% | 0.0% |
| Q4 2022 | $1,892,685 | -8.1% | 164,868 | +0.9% | 0.00% | 0.0% |
| Q3 2022 | $2,060,000 | +4.1% | 163,453 | -12.6% | 0.00% | 0.0% |
| Q2 2022 | $1,978,000 | -33.7% | 186,937 | +1.9% | 0.00% | 0.0% |
| Q1 2022 | $2,983,000 | +36.6% | 183,447 | +16.4% | 0.00% | 0.0% |
| Q4 2021 | $2,183,000 | -3.5% | 157,562 | +0.0% | 0.00% | 0.0% |
| Q3 2021 | $2,263,000 | +210.9% | 157,547 | +242.0% | 0.00% | – |
| Q2 2021 | $728,000 | +44.4% | 46,063 | -7.1% | 0.00% | – |
| Q1 2021 | $504,000 | +31.2% | 49,572 | -3.9% | 0.00% | – |
| Q4 2020 | $384,000 | +204.8% | 51,583 | +39.9% | 0.00% | – |
| Q3 2020 | $126,000 | -35.4% | 36,869 | -9.9% | 0.00% | – |
| Q2 2020 | $195,000 | +134.9% | 40,921 | -1.0% | 0.00% | – |
| Q1 2020 | $83,000 | -38.1% | 41,327 | +6.7% | 0.00% | – |
| Q4 2019 | $134,000 | +63.4% | 38,725 | +35.5% | 0.00% | – |
| Q3 2019 | $82,000 | 0.0% | 28,582 | +32.8% | 0.00% | – |
| Q2 2019 | $82,000 | -47.8% | 21,525 | +11.4% | 0.00% | – |
| Q1 2019 | $157,000 | +0.6% | 19,315 | 0.0% | 0.00% | – |
| Q4 2018 | $156,000 | +20.9% | 19,315 | +14.5% | 0.00% | – |
| Q3 2018 | $129,000 | +43.3% | 16,862 | +7.2% | 0.00% | – |
| Q2 2018 | $90,000 | +5.9% | 15,730 | -11.9% | 0.00% | – |
| Q1 2018 | $85,000 | -29.2% | 17,849 | -26.4% | 0.00% | – |
| Q4 2017 | $120,000 | +6.2% | 24,265 | +12.6% | 0.00% | – |
| Q3 2017 | $113,000 | +10.8% | 21,553 | +17.5% | 0.00% | – |
| Q2 2017 | $102,000 | -30.1% | 18,346 | +4.9% | 0.00% | – |
| Q1 2017 | $146,000 | +29.2% | 17,486 | -1.4% | 0.00% | – |
| Q4 2016 | $113,000 | +135.4% | 17,727 | +62.5% | 0.00% | – |
| Q3 2016 | $48,000 | +54.8% | 10,906 | 0.0% | 0.00% | – |
| Q2 2016 | $31,000 | +3.3% | 10,906 | 0.0% | 0.00% | – |
| Q1 2016 | $30,000 | -73.2% | 10,906 | 0.0% | 0.00% | – |
| Q4 2015 | $112,000 | -8.9% | 10,906 | 0.0% | 0.00% | – |
| Q3 2015 | $123,000 | -27.6% | 10,906 | 0.0% | 0.00% | – |
| Q2 2015 | $170,000 | +75.3% | 10,906 | 0.0% | 0.00% | – |
| Q1 2015 | $97,000 | -27.1% | 10,906 | 0.0% | 0.00% | – |
| Q4 2014 | $133,000 | +20.9% | 10,906 | 0.0% | 0.00% | – |
| Q3 2014 | $110,000 | – | 10,906 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |